Anodal tDCS increases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in episodic migraine.
During the interictal phase, the cerebral cortex is characterised by hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical evoked responses. Such habituation deficit can be shown in the visual cortex by the study of visual evoked potentials (VEP) and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. In healthy subjects and in migraineurs between attacks, anodal tDCS increases VEP habituation and 1st block amplitude. In a proof-of-concept trial, the investigators have shown in 10 episodic migraine without aura patients that 2 weekly 15-minute sessions for 8 weeks of anodal tDCS over the visual cortex significantly decreased attack frequency, migraine days, attack duration and acute medication intake for more than 4 weeks after the last treatment session. This randomized trial was designed to prove the preventive effect in episodic migraine of anodal tDCS over the visual cortex compared to sham stimulation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
2mA during 30sec
Roberta Baschi
Liège, Belgium
Migraine frequency
The investigators evaluate the migraine frequency at baseline (2 months), during the treatment and 2 months after its end.
Time frame: 6 months
Migraine intensity
The investigators evaluate migraine intensity at baseline, during the treatment and 2 months after its end.
Time frame: 6 months
Acute medication intake
The investigators evaluate acute medication intake at baseline, during the treatment and 2 months after its end.
Time frame: 6 months
Attack duration
The investigators evaluate attack duration at baseline, during the treatment and 2 months after its end.
Time frame: 6 months
Score on psychological scales
The investigators evaluate score on psychological scales at baseline, during the treatment and 2 months after its end.
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.